TY - JOUR AB - Berberine has multiple clinical applications, including the treatment of tumors, diabetes, cardiovascular diseases, hyperlipidemia, inflammation, bacterial and viral infections, cerebral ischemic injuries, mental diseases, Alzheimer's disease and osteoporosis. In the present study, the neuroprotective effect of berberine agonist rescue learning and memory in severe traumatic brain injury (TBI), and the possible mechanism underlying these observations was explored. The protective effect of berberine agonist significantly recovered learning and memory skills, attenuated brain edema and inhibited matrix metalloproteinase‑3 and ‑9 protein expression in mice with severe TBI. Berberine agonist significantly reduced inflammation, oxidative stress and apoptosis levels in mice with severe TBI. Berberine agonist promoted choline acetyltransferase activity and inhibited the activity of acetylcholinesterase. Collectively, results of the present study revealed that the neuroprotective effect of berberine agonist rescues learning and memory skills in severe TBI. AD - Department of Emergency, Gansu Provincial Hospital, Lanzhou, Gansu 730000, P.R. China Department of Neurological Rehabilitation, Gansu Provincial Hospital, Lanzhou, Gansu 730000, P.R. China AU - Wang,Jianping AU - Zhang,Yamin DA - 2018/05/01 DO - 10.3892/mmr.2018.8674 EP - 6886 IS - 5 JO - Mol Med Rep KW - berberine severe traumatic brain injury learning and memory p38 mitogen‑activated protein kinase PY - 2018 SN - 1791-2997 1791-3004 SP - 6881 ST - Neuroprotective effect of berberine agonist against impairment of learning and memory skills in severe traumatic brain injury via Sirt1/p38 MAPK expression T2 - Molecular Medicine Reports TI - Neuroprotective effect of berberine agonist against impairment of learning and memory skills in severe traumatic brain injury via Sirt1/p38 MAPK expression UR - https://doi.org/10.3892/mmr.2018.8674 VL - 17 ER -